The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Bristol/AZ Dapagliflozin Likely Headed To Approval on Second Review; Case Study In Use Of Dispute Resolution Dec. 10, 2013
- Takeda’s Vedolizumab: Committee Supports Approval in Crohn’s & UC; Timing Will Depend on Risk Management Plan Dec. 10, 2013
- Generic Drug “Super Office” Structure Finalized, CDER’s Woodcock Takes Over Outside Quality Function Dec. 10, 2013
See More Research Notes